IP Library Granted Patent US 10,434,214
Granted Patent B2
US 10,434,214 · App. 15/727,916 · Granted Oct 8, 2019

Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Inventors: Xiaojie Yu (Orange, CA); Nicholas J. Manesis (Escondido, CA); Jacob Pollock (Honolulu, HI)
Assignee: Allergan, Inc.
A61L27/24A61K8/042A61K8/735A61L27/26A61L27/3695A61L27/52A61Q19/08A61K2800/91A61L2400/06A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,214
App. No.
15/727,916
Granted
Oct 8, 2019
Kind
B2
Abstract

Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.

Claims (21)

1. A soft tissue aesthetic product comprising:

an injectable hydrogel composition comprising:

(i) water; and

(ii) a hyaluronic acid crosslinked with a collagen via a plurality of crosslink units, wherein at least a portion of the crosslink units comprise an amide bond; and wherein the hyaluronic acid concentration is from 6 mg/ml to 20 mg/ml; the collagen concentration is from 3 mg/ml to 12 mg/ml; the hyaluronic acid:collagen weight ratio is from 1:1 to 7:1; and the hydrogel has a storage modulus value of between 850 Pa and 5,000 Pa.

2. The product of claim 1 , wherein the product further comprises a label, and wherein the label comprises instructions for injecting the hydrogel composition into a human tissue.

3. The product of claim 1 , wherein the collagen is collagen type I, collagen type Ill, or a combination thereof.

4. The product of claim 3 , wherein the collagen is collagen type I.

5. The product of claim 3 , wherein the collagen is derived from a human or porcine source.

6. The product of claim 1 , wherein the hyaluronic acid has a molecular weight of about 1,000,000 Da to about 5,000,000 Da.

7. The product of claim 1 , wherein the hyaluronic acid has a molecular weight of about 1,000,000 Da to about 3,000,000 Da.

8. The product of claim 1 , wherein the ratio of the hyaluronic acid to the collagen ranges from 1:1 to 2:1.

9. The product of claim 1 , wherein the ratio of the hyaluronic acid to the collagen is 1:1.

10. The product of claim 1 , wherein the hydrogel has a storage modulus value of between 1,000 Pa and 5,000 Pa.

11. The product of claim 1 , wherein the hydrogel has a hyaluronic acid concentration of 12 mg/ml or 16 mg/ml.

12. The product of claim 1 , wherein the hydrogel has a collagen concentration of 6 mg/ml, 8 mg/ml or 12 mg/ml.

13. The product of claim 1 , wherein the hydrogel has a hyaluronic acid concentration of 12 mg/ml and a collagen concentration of 6 mg/ml.

14. The product of claim 1 , wherein the hydrogel has a hyaluronic acid concentration of 12 mg/ml and a collagen concentration of 12 mg/ml.

15. The product of claim 1 , wherein the hydrogel has a hyaluronic acid concentration of 16 mg/ml and a collagen concentration of 8 mg/ml.

16. The product of claim 2 , wherein the injection is intradermal.

17. The product of claim 2 , wherein the injection is subcutaneous.

18. The product of claim 2 , wherein the human tissue contains adipose tissue.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: POLLOCK, JACOB F.
To: ALLERGAN, INC.
Reel/Frame 050715/0594 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2017
From: YU, XIAOJIE; MANESIS, NICHOLAS J.
To: ALLERGAN, INC.
Reel/Frame 043822/0041 →
Continuity (8)
Continuation 15609967 · May 31, 2017
Continuation 14962897 · Dec 8, 2015
Division 13667581 · Nov 2, 2012
Continuation In Part 13605565 · Sep 6, 2012
Continuation In Part 13603213 · Sep 4, 2012
Provisional Application 61555970 · Nov 4, 2011
Provisional Application 61531533 · Sep 6, 2011
Related Publication 20180028719A1 · Feb 1, 2018